 Home > Popular Keywords > Keyword List B > bc cancer folfox

bc cancer folfox

Your source for the latest bc cancer folfox articles. Follow bc cancer folfox trends, innovations and developments on echemi.com.

J Clin Oncol: A randomized trial by Professor Ming Shi's team from Sun Yat-sen University Cancer

 Time of Update: 2021-10-20

In a previous phase II clinical trial, the use of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for hepatic artery infusion chemotherapy (HAIC) resulted in greater than transarterial chemoembolization (TACE) in unresectable large hepatocellular carcinoma.
Prof. Chunfang Hao | 2021 CSCO BC Diagnosis and Treatment Guidelines Update: Update Points and Progress of HR Positive Advanced Breast Cancer

 Time of Update: 2021-05-09

) Annual Conference were held in Beijing from April 9th to 10th in the form of "online + offline". As one of the most influential academic events in the field of breast cancer in China, domestic and foreign
2021 CSCO BC|Professor Yang Jin: Targeted Joint Strategy of Endocrine Therapy for Breast Cancer

 Time of Update: 2021-05-08

The BYLieve study evaluated the efficacy of Alpelisib combined with endocrine therapy for CDK4/6 inhibitor + AI/fulvestrant treatment progress in HR+/HER2-, PIK3CA mutant breast cancer patients.
Professor Wang Kun: Interpretation of the key points of the 2021 CSCO BC diagnosis and treatment

 Time of Update: 2021-04-23

(CSCO BC) Annual Meeting was successfully held in Beijing in the form of "online + offline". At this meeting, the "2021 CSCOBC Diagnosis and Treatment Guidelines" was officially released.
Prof. Yingying Xu: From population selection to plan formulation, "re-understanding" of neoadjuvant treatment for breast cancer | 2021 CSCO BC

 Time of Update: 2021-04-23

In addition, based on the results of the KATHERINE study, St Gallen experts support all HER2+ tumors with residual lesions after standard neoadjuvant treatment, even patients with residual invasive tumors less than 5 mm should receive adjuvant T-DM1 treatment.
2021 CSCO Breast Cancer Guidelines: Interpretation of the updated key points of HER2+ neoadjuvant treatment for early breast cancer | 2021 CSCO BC

 Time of Update: 2021-04-23

>In view of the fact that the concept of “neoadjuvant treatment for T1c patients” has not been verified by clinical research and practice, the CSCO breast cancer guidelines still adopt the most advanced and feasible selection criteria currently
Professor Liu Jian: Re-discussion on several hot issues of endocrine therapy for breast cancer | 2021 CSCO BC

 Time of Update: 2021-04-18

Table 2 Efficacy and safety differences of first-line targeted endocrine therapy In the PALOMA-2 study, patients were randomly assigned to the pipercillil + letrozole group and the placebo + letrozole group at 2:1, and the study reached the primary endpoint.
Professor Yang Jin: A new strategy for breast cancer endocrine combined targeted therapy | 2021 CSCO BC

 Time of Update: 2021-04-18

Jiaotong University shared a new strategy for breast cancer endocrine combined targeted therapy, bringing new options for clinical practice of breast cancer patients. Professor Yang Jin’s latest data in 2020
Professor Qiang Liu: Immunotherapy brings more hope to breast cancer | 2021 CSCO BC

 Time of Update: 2021-04-18

In the early study KEYNOTE-086, the results showed that PD-1/PD-L1 monotherapy has a certain effect on metastatic triple-negative breast cancer (mTNBC), but the tumor The remission rate is only 5-26%; the KEYNOTE-119 study compared the efficacy of pembrolizumab vs.
JAMA: The effect of celecoxib combined with FOLFOX standard adjuvant chemotherapy on the disease-free survival rate of colon cancer patients

 Time of Update: 2021-04-17

Recently, researchers investigated the effect of adding celecoxib to the adjuvant chemotherapy regimen of fluorouracil, calcium leucovorin and oxaliplatin (FOLFOX) on the disease-free survival rate of patients with stage III colon cancer .
Lancet Oncol: Active symptom control combined with FOLFOX chemotherapy can effectively prolong

 Time of Update: 2021-04-14

Recently, The Lancet Oncology published a study in which patients with advanced biliary tract cancer who had
JCO: Pegilo decakin and FOLFOX second-line therapy failed to improve the efficacy of giesythabin incurable metastatic pancreatic cancer

 Time of Update: 2021-02-24

Pegilodecakin (PEG) combined calcium folate, fluorouracil and FOLFOX for second-line treatment of Gisitabin refractional pancreatic cancer (PDAC), failed to improve its OS, PFS or ORR, and no new safety signals were observed.
CSCO BC Annual Meeting . . . Professor Li Jin, Professor Jiang Zefei: Breast cancer bone metastasis ushered in innovative drugs.

 Time of Update: 2020-07-17

July 10-11, 2020, has been the attention of the CSCO Breast Cancer Conference and 2020 National Breast Cancer Conference successfully held in Beijing! Covering the "cutting-edge science, innovative drugs, guide consensus, celebrity perspective, big

Related Keywords

folfox stomach cancer folfox for rectal cancer folfox vs folfiri colon cancer folfox avastin colorectal cancer folfox mucinous ovarian cancer bc cancer pembrolizumab carfilzomib bc cancer bc cancer drug index

Hot Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

banned insecticide(178)

behr paint company(103)

beijing dumpling(138)

bevnet live(106)

buffington homes(84)

borger management(71)

burette stand(72)

biodiesel tax credit(42)

bodyfit plan(96)

bakersfield sound co(59)

What's trending

Top Keywords

box cardboard box

b cell secreted antibody

best wood for water contact

b cells and plasma cells

b cells and t cells are

b 6 foods

bulk contact paper

botanical contact paper

best cereal for high cholesterol

b 973 high

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.